Evidence map›Paper›PMID 37593573›Full record

ArticleRSC medicinal chemistry2023

Romain Amador, Ali Tahrioui, Magalie Barreau, Olivier Lesouhaitier, Michael Smietana, Guillaume Clavé

Abstract read
In one paragraph

Article in RSC medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Click Chemistry-Enabled Parallel Synthesis ofMolecules (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Romain AmadorInstitut des Biomolécules Max Mousseron, Université de Montpellier, CNRS, ENSCM 1919 route de Mende 34095 Montpellier France guillaume.clave@cnrs.fr michael.smietana@umontpellier.fr.ORCID https://orcid.org/0000-0002-7498-0334
Ali TahriouiUniv Rouen Normandie, Université Caen Normandie, Normandie Univ, Communication Bactérienne et Stratégies Anti-infectieuses (CBSA) UR 4312 F-76000 Rouen France.ORCID https://orcid.org/0000-0003-4064-820X
Magalie BarreauUniv Rouen Normandie, Université Caen Normandie, Normandie Univ, Communication Bactérienne et Stratégies Anti-infectieuses (CBSA) UR 4312 F-76000 Rouen France.ORCID https://orcid.org/0000-0002-9509-6054
Olivier LesouhaitierUniv Rouen Normandie, Université Caen Normandie, Normandie Univ, Communication Bactérienne et Stratégies Anti-infectieuses (CBSA) UR 4312 F-76000 Rouen France.ORCID https://orcid.org/0000-0001-8235-8919
Michael SmietanaInstitut des Biomolécules Max Mousseron, Université de Montpellier, CNRS, ENSCM 1919 route de Mende 34095 Montpellier France guillaume.clave@cnrs.fr michael.smietana@umontpellier.fr.ORCID https://orcid.org/0000-0001-8132-7221
Guillaume ClavéInstitut des Biomolécules Max Mousseron, Université de Montpellier, CNRS, ENSCM 1919 route de Mende 34095 Montpellier France guillaume.clave@cnrs.fr michael.smietana@umontpellier.fr.ORCID https://orcid.org/0000-0001-6401-0935

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sulfonamides are the oldest class of antibiotics, discovered more than 80 years ago. They are still used today despite the appearance of drug resistance phenomena that limit their prescription. Since the discovery and use of the first sulfa drugs, many analogues have been synthesized in order to obtain new active molecules able to circumvent bacterial resistance. Structurally similar to sulfonamide, the

Identifiers

PMID37593573
PMCPMC10429802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.